Daily Bulletin

Business Mentor

.

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Alterity to present at the 7th International Congress of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format from February 26-27, 2021.

The event is a world leading conference on Multiple System Atrophy (MSA), a rapidly progressive and debilitating neurodegenerative disease without approved treatment. MSA is characterized by motor symptoms similar to those in Parkinson's disease and autonomic failure that manifests as impaired ability to maintain normal blood pressure, bowel and bladder function. MSA2021 promotes international collaboration and the acceleration of research for MSA treatments. With the event being postponed in 2020 due to COVID-19, this year's congress will be held in a live and on-demand virtual format.

Alterity's presentation will be featured as part of the Congress' poster presentations, available online for attendees to access on demand.

Alterity will be presenting further information on ATH434, its lead development candidate for the treatment of MSA. The new results to be presented include data on blood pressure following change in body position, which demonstrate that ATH434 does not lower blood pressure when subjects move to the standing position. This is an important safety finding considering impaired maintenance of blood pressure is a cardinal problem in MSA, thus extending the cardiac and overall safety profile previously presented.

As part of its Phase 2 program, Alterity is also undertaking a natural history study in collaboration with Vanderbilt University Medical Center, the results of which will inform the design of the treatment study targeted to start in 2H '21 .

Commenting on the Company's participation in this year's congress, Alterity Therapeutics CEO Dr David Stamler remarked that "This scientific meeting includes the leading MSA researchers from around the globe, and Alterity is eager to share the emerging clinical data as we advance our Phase 2 program".

Authorisation & Additional information

This announcement was authorised by David Stamler, CEO of Alterity Therapeutics Limited.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/alterity-to-present-at-the-7th-international-congress-of-multiple-system-atrophy-301236319.html

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/3292424_CN92424_0

Business News

How to Get the Best Value When Buying Cardboard Boxes

Cardboard boxes have become an indispensable part of daily life, whether for moving houses, shipping products or simply for storage purposes. The key to making the most out of these versatile contai...

Daily Bulletin - avatar Daily Bulletin

BYD Expands in Australia: Introducing Chinese Dealerships and Pioneering Innovative Operations

Recently, BYD has been generating significant buzz with the launch of its two new stores in Melbourne and Sydney, revealing some exciting developments. Notably, BYD’s Chairman, Wang Chuanfu, graced ...

Daily Bulletin - avatar Daily Bulletin

Deciphering the Intricacies of Scrap Copper Prices in Melbourne: A Comprehensive Analysis

Introduction In the bustling metropolis of Melbourne, where innovation meets industry, the scrap copper market forms an integral part of the city's economic landscape. From the scrapyards scattered...

Daily Bulletin - avatar Daily Bulletin

Tomorrow Business Growth